Stone X Group Inc. Gilead Sciences, Inc. Transaction History
Stone X Group Inc.
- $2.06 Trillion
- Q2 2025
A detailed history of Stone X Group Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Stone X Group Inc. holds 4,108 shares of GILD stock, worth $484,127. This represents 0.02% of its overall portfolio holdings.
Number of Shares
4,108
Previous 5,676
27.63%
Holding current value
$484,127
Previous $636 Million
28.38%
% of portfolio
0.02%
Previous 0.26%
Shares
31 transactions
Others Institutions Holding GILD
# of Institutions
2,328Shares Held
1.02BCall Options Held
12.1MPut Options Held
9.13M-
Black Rock Inc. New York, NY121MShares$14.2 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA119MShares$14.1 Billion0.22% of portfolio
-
State Street Corp Boston, MA59.2MShares$6.98 Billion0.25% of portfolio
-
Capital World Investors Los Angeles, CA46.3MShares$5.46 Billion0.78% of portfolio
-
Wellington Management Group LLP Boston, MA37.5MShares$4.42 Billion0.79% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $148B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...